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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To identify the diDerent types of educational interventions, how they are delivered, and to determine their eDectiveness and safety in
people with IBD.
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B A C K G R O U N D
Description of the condition
Inflammatory bowel disease (IBD) is an umbrella term for a range of
conditions that cause inflammation to the human gastrointestinal
tract, with the most prominent ones being ulcerative colitis and
Crohn's disease. Symptoms can include pain, cramping, swelling,
diarrhoea, weight loss and tiredness. The aetiology of IBD is
still undetermined but it is thought to be caused via a complex
interaction of genetic and environmental factors (De Souza 2017).
More specifically, it is thought that IBD is due to an aberrant
immune response to the gut commensal flora in a genetically
susceptible individual (Pizarro 2019). IBD is a life-long condition
for which currently there is no cure. Treatment options include
medications, lifestyle and diet changes, and surgery with the aim of
inducing and maintaining remission of the disease. It is estimated
that more than 6.8 million people are living with IBD globally
with incidences of the disease rising especially in regions that are
newly adopting western lifestyles (Jairath 2020; Kaplan 2017). Apart
from its physical manifestations, IBD can have a serious impact
on patients' psychological and social well-being by limiting the
patient's ability to take part in social activities and engagements.
It also places a significant burden on healthcare systems, with an
estimated EUR 4.6 billion to EUR 5.6 billion of annual healthcare
costs attributed to IBD in Europe and USD 7.2 billion in the USA
(Burisch 2013; Windsor 2019).
Description of the intervention
Patient educational interventions aim to deliver structured
information to the recipient of the intervention and there is
evidence to suggest patient education can have positive eDects in
other chronic diseases (Anderson 2017; HowcroK 2016). However,
the content, delivery method, duration and specific purposes of
any given intervention can vary considerably and there are no set
standards for any of these parameters.
Local resources and healthcare systems, as well as individual
patient factors, can have a major impact on patient education.
Therefore, there is a need to understand whether such
interventions can aDect patient outcomes, and how and why they
aDect patient outcomes.
How the intervention might work
Education will enhance patient knowledge surrounding IBD.
However, the question of how this may impact on their disease
outcomes is complex. One point of focus has been about advising
patients how to determine when their disease is deteriorating so
they can contact their healthcare provider. Improving medication
adherence, recognising adverse eDects and when to report them,
and improving compliance might be some of the ways patient
education interventions might work.
IBD can aDect patients' daily lives in several ways and can lead
to a lower health-related quality of life. Together with physician-
led management, self-management and knowledge about their
disease can play an important role in giving patients control over
their condition. IBD educational interventions can provide patients
with important information and advice towards that end.
Why it is important to do this review
More clarity on the types of educational interventions targeting
people with IBD that have been researched at a randomised
controlled trial (RCT) level, what they entail and to what extent they
are eDective is vital for people with IBD to make better informed
decisions for the self-management of their condition.
It is important to review systematically the evidence that has
sought to address deficits identified in education (NRAD 2015),
and to assess the attributes of training packages, so they can
be applied eDectively (Norcini 2011). The extent to which we can
answer 'how' training can be designed, 'why' it is eDective and 'for
whom and when' will depend on descriptive data within primary
studies, but it is important to highlight this information to help
professionals understand and deliver health education in a reliable
and reproducible manner (Gordon 2011; Gordon 2013).
O B J E C T I V E S
To identify the diDerent types of educational interventions, how
they are delivered, and to determine their eDectiveness and safety
in people with IBD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published, unpublished and ongoing RCTs that compare
educational interventions targeted at people with IBD to any other
type of intervention or no intervention.
Types of participants
People with IBD of all ages.
Types of interventions
Any type of formal or informal educational intervention, lasting
for any time. Delivery methods can include face-to-face or remote
educational sessions or workshops, guided study via the use of
printed or online materials, the use of mobile applications or any
other method that delivers information to patients.
We will list all intervention and comparator groups in the
'Characteristics of included studies' table.
Types of outcome measures
Primary outcomes
• Disease activity at study end, using a recognised disease activity
scoring system as described by the study authors.
• Flare-ups or relapse measured clinically, endoscopically or
histologically.
• Quality of life at study end using validated scales or tools.
Secondary outcomes
• Number of episodes accessing health care (outpatient, remote
or inpatient.)
• Change in disease activity using a recognised score.
• Change in quality of life using a validated tool.
• Medication adherence.
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• Patient knowledge or skill (or both) as measured by a study.
This will be specific assessment at study end (this outcome
has a significant risk of heterogeneity that will probably
prevent meta-analysis) and will be classified using Kirkpatrick's
modified hierarchy, a model for analysing and evaluating the
results of training and educational programmes (see 'Qualitative
synthesis')
Adverse e8ects
• Total adverse eDects (serious and minor).
• Adverse events leading to withdrawal.
Qualitative synthesis
We will record and synthesise the following to characterise
educational interventions.
• Educational content (primary material, learning outcomes,
theoretical underpinning).
• Teaching attributes of training programmes used (staD and
resource requirements, length of course, methods including
whether e-learning, asynchronous or synchronous, any follow-
up service or session).
• Any knowledge assessment, including method used and
reported pre- and post-test scores. Note if suDiciently
homogeneous tests and education are deployed (such as
standardised courses and testing materials), there may be
scope for meta-analysis of test data. However, pilot searches
performed suggest no such homogeneous methods exist and,
therefore, it is not currently predicted that such analysis will
possible. Therefore, a qualitative analysis is planned.
Search methods for identification of studies
Electronic searches
We will search the following sources to the date of search and will
place no restrictions on the language of publication.
• Cochrane Central Register of Controlled Trials (CENTRAL; via
Ovid, from inception) (Appendix 1).
• MEDLINE (via Ovid, from 1946) (Appendix 2).
• Embase (via Ovid, from 1974) (Appendix 3).
• PsycINFO (via Ovid, from 1987).
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature) (via EBSCO, from 1981).
• AMED (Allied and Complementary Medicine database) (via Ovid,
from 1985).
• ClinicalTrials.gov (www.clinicaltrials.gov).
• World Health Organization International Clinical Trials Registry
Platform (ICTRP) (www.who.int/trialsearch/).
Searching other resources
As complementary search methods, we will carefully check relevant
systematic reviews for studies for potential inclusion in our review.
In addition, we will scrutinise the references of included studies in
our review. We will seek unpublished trials by contacting experts
in the field and we will scan the Internet and abstracts submitted
to major international congresses from the three years prior to the
search to capture any studies presented but not yet published in
full.
We will attempt to obtain translations of papers when necessary.
Data collection and analysis
We will carry out data collection and analysis according to the
methods recommended in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2020).
Selection of studies
Two review authors will independently screen the titles and
abstracts identified from the literature search. We will discard
studies that do not meet the inclusion criteria. We will then obtain
the full report of studies that appear to meet our inclusion criteria
or for which there is insuDicient information to make a final
decision. Two review authors will independently assess the reports
to establish whether the studies meet the inclusion criteria. We will
resolve disagreements by discussion, with a third review author
consulted if resolution is not possible. We will enter studies rejected
at this or subsequent stages in the 'Characteristics of excluded
studies' tables and record the main reason for exclusion. We will
record the selection process in suDicient detail to complete a
PRISMA flow diagram.
Where studies have multiple publications, we will identify and
exclude duplicates, and collate the reports of the same study so
that each study, rather than each report, is the unit of interest for
the review, and such studies have a single identifier with multiple
references.
Data extraction and management
Two review authors will independently carry out data extraction
using piloted data extraction forms. We will extract relevant data
from full-text articles that meet the inclusion criteria including:
• trial setting: country and number of trial centres;
• methods: study design, total study duration and date;
• participant characteristics: age, sociodemographics, ethnicity,
diagnostic criteria and total number;
• eligibility criteria: inclusion and exclusion criteria;
• intervention and comparator – this will include description
of the learning outcomes planned for the intervention by the
teacher or designer, methods of education used, target audience
and any resources required);
• patient outcomes: patient outcome definition, unit of
measurement and time of collection;
• outcomes from education: educational outcomes, if described,
reported and classified as either satisfaction/reaction, attitudes
or knowledge and skills;
• results: number of participants allocated to each group, missing
participants, sample size;
• funding source.
Assessment of risk of bias in included studies
During data extraction, two review authors will independently
assess all studies meeting the inclusion criteria for their risk of bias
using criteria outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2020). The domains that we will
assessed are as follows.
• Sequence generation (selection bias).
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• Allocation concealment (selection bias).
• Blinding of participants and personnel (performance bias).
• Blinding of outcome assessment (detection bias).
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Other bias.
We will judge the studies to be at low, high or unclear risk of bias
for each domain assessed, based on guidance in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2020).
AKer data extraction, the two review authors will compare the
extracted data to discuss and resolve discrepancies before the data
are transferred into the 'Characteristics of included studies' table.
For cluster RCTs, we intend to judge risk of bias as prescribed in
section 23.1.2 "Assessing risk of bias in cluster-randomized trials"
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2020).
Measures of treatment e8ect
For dichotomous outcomes, we will express treatment eDect as
risk ratios (RR) with corresponding 95% confidence intervals (CIs).
For continuous outcomes, we will express the treatment eDect as
mean diDerence (MD) with 95% CI if studies use the same scales and
methods. However, if studies assess the same continuous outcome
using diDerent methods, we will estimate the treatment eDect using
the standardised mean diDerence (SMD) with 95% CIs. We will
present SMDs as standard deviation units and interpret them as
follows: 0.2 represents a small eDect, 0.5 a moderate eDect and 0.8
a large eDect.
Unit of analysis issues
The participant will be the unit of analysis. For studies comparing
more than two intervention groups, we will make multiple pair-
wise comparisons between all possible pairs of intervention
groups. To avoid double counting, we intend to divide out
shared intervention groups evenly among the comparisons. For
dichotomous outcomes, we plan to divide up both the number
of events and the total number of participants. For continuous
outcomes, we will divide up the total number of participants and
leave the means and standard deviations unchanged. We will
include cross-over studies if data are separately reported before
and aKer cross-over and we will only use data from the first
phase for our analysis. We do not anticipate finding any cluster
RCTs; however, we will use study data only if the authors have
used appropriate statistical methods in taking clustering eDect
into account. We will also exclude cluster RCTs from a sensitivity
analysis to assess their impact on the results.
Dealing with missing data
We aim to contact authors where there are missing data or studies
have not reported data in suDicient detail. We will attempt to
estimate missing standard deviations using relevant statistical
tools and calculators if studies report standard errors. Studies that
fail to report measures of variance will be judged as being at high
risk of selective reporting bias.
Assessment of heterogeneity
We will scrutinise studies to ensure that they are clinically
homogeneous in terms of participants, intervention, comparator
and outcome. To test for statistical heterogeneity, we will use a Chi2
test. A P value of less than 0.1 will give an indication of the presence
of heterogeneity. Inconsistency will be quantified and represented
by the I2 statistic. The thresholds will be interpreted as follows
(Higgins 2020):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%; may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
Most reporting biases will be minimised by using an inclusive
search strategy. We will investigate publication bias using a funnel
plot if there are 10 or more studies. The magnitude of publication
bias will be determined by visual inspection of the asymmetry of
the funnel plot. In addition, we will test funnel plot asymmetry
by performing a linear regression of intervention eDect estimate
against its standard error, weighted by the inverse of the variance
of the intervention eDect estimate (Egger 1997).
Data synthesis
To summarise the study characteristics, we intend to conduct
a narrative synthesis of all the included studies. We will then
carry out a meta-analysis if there are two more studies that have
assessed similar populations, interventions and outcomes. We will
analyse studies from paediatric populations, adult populations
and diDerent subintervention types separately. We will synthesise
data using the random-eDects model in Review Manager 5 (Review
Manager 2014). We will combine eDect estimates of studies which
report data in a similar way, in the meta-analysis. We will pool
RRs for dichotomous outcomes and MDs or SMDs for continuous
outcomes with 95% CIs. Where we are unable to carry out a meta-
analysis (e.g. due to lack of uniformity in data reporting), we will
present a narrative summary of the included studies.
Subgroup analysis and investigation of heterogeneity
If there is heterogeneity, we will investigate possible causes and
address them using methods described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2020). We will
undertake subgroup analyses of potential eDect modifiers if there
are 10 studies or more. If enough data are available, we will perform
subgroup analyses by age, gender and disease type.
It is recognised that the nature of the studies likely to be included
in this review may be capricious and heterogeneous in a number
of key clinical and methodological ways that cannot be fully
predicted. If such factors are identified and become relevant to
ensure integrity of the analysis, modifications to this list may be
needed. These will be fully reported by the authors.
Sensitivity analysis
Where possible, we plan to undertake a sensitivity analysis on
the primary outcome of 'disease activity at study end', to assess
whether the findings of the review are robust to the decisions
made during the review process. In particular, we intend to exclude
studies at high or unclear risk of bias due to allocation bias and
performance bias from analyses that have a mix of studies with
diDerent risk of bias judgements. Where data analyses include
studies with reported and estimated standard deviations, we plan
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to exclude those with estimated standard deviations to assess
whether this aDects the findings of the review. We will investigate
whether the choice of model (fixed versus random) impacts the
results to explore heterogeneity.
Summary of findings and assessment of the certainty of the
evidence
We will present the main results in a 'Summary of findings'
table. Each comparison and primary outcome will be exported
to GRADEprofiler soKware (developed by the GRADE Working
Group) for quality assessment (GRADE 2015). We will include all
three primary outcomes. We will apply GRADE to any additional
comparisons and present these in additional tables. Based on risk
of bias, inconsistency, imprecision, indirectness and publication
bias, we will rate the certainty of the evidence for each outcome as
high, moderate, low or very low. These ratings have been defined
as follows.
• High: further research is very unlikely to change our confidence
in the estimate of eDect.
• Moderate: further research is likely to have an important impact
on our confidence in the estimate of eDect and may change the
estimate.
• Low: further research is very likely to have an important impact
on our confidence in the estimate of eDect and is likely to change
the estimate.
• Very low: any estimate of eDect is very uncertain.
We will justify all decisions to downgrade the quality of studies
using footnotes and we will make comments to aid reader's
understanding of the review where necessary.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy (Ovid)
1. exp Inflammatory bowel diseases/
2. (inflammatory bowel disease* or IBD).tw,kw.
3. crohn*.tw,kw.
4. (colitis or regional enteritis or proctocolitis or colorectitis).tw,kw.
5. (UC or CD).tw,kw.
6. or/1-5
7. exp patient education handout/
8. exp Education/
9. exp patient medication knowledge/
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10.((patient* or consumer*) adj3 (educat* or literacy or training or workshop* or handout or session* or printed or print online or internet
or booklet* or poster* or paper-based or pamphlet* or brochure* or leaflet* or circular* or flyer* or program* or teaching or knowledge
or information)).tw,kw.
11.((information or education*) adj3 (workshop* or handout or session* or printed or print or online or internet or booklet* or poster* or
written material* or paper-based or pamphlet* or brochure* or leaflet* or circular* or flyer* or program* or knowledge)).tw,kw.
12.((print or printed or education*) adj2 intervention*).tw,kw.
13.(health education or health information or health literacy).tw,kw.
14.or/7-13
15.6 and 14
Appendix 2. MEDLINE search strategy (Ovid)
1. exp Inflammatory bowel diseases/
2. (inflammatory bowel disease* or IBD).tw,kw.
3. crohn*.tw,kw.
4. (colitis or regional enteritis or proctocolitis or colorectitis).tw,kw.
5. (UC or CD).tw,kw.
6. or/1-5
7. exp patient education handout/
8. exp Education/
9. exp patient medication knowledge/
10.((patient* or consumer*) adj3 (educat* or literacy or training or workshop* or handout or session* or printed or print online or internet
or booklet* or poster* or written material* or paper-based or pamphlet* or brochure* or leaflet* or circular* or flyer* or program* or
teaching or knowledge or information)).tw,kw.
11.((information or education*) adj3 (workshop* or handout or session* or printed or print or online or internet or booklet* or poster* or
written material* or paper-based or pamphlet* or brochure* or leaflet* or circular* or flyer* or program* or knowledge)).tw,kw.
12.((print or printed or education*) adj2 intervention*).tw,kw.










23.exp animals/ not humans.sh.
24.22 not 23
25.15 and 24
Note: Lines 16-24. RCT filter: Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity-
maximising version (2008 revision); Ovid format” We made the following minor revisions: we used “random*” instead of “randomized.ab”
or “randomly.ab.” to capture word variations such as “randomised, randomization, random”; we removed “drug therapy.fs.” from the above
filter as this review is not related to drug therapy.
Appendix 3. Embase search strategy (Ovid)
1. exp inflammatory bowel disease/
2. (inflammatory bowel disease* or IBD).tw,kw.
3. crohn*.tw,kw.
4. (colitis or regional enteritis or proctocolitis or colorectitis).tw,kw.
5. (UC or CD).tw,kw.
6. or/1-5
7. exp education/
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8. ((patient* or consumer*) adj3 (educat* or literacy or training or workshop* or handout or session* or printed or print online or internet
or booklet* or poster* or written material* or paper-based or pamphlet* or brochure* or leaflet* or circular* or flyer* or program* or
teaching or knowledge or information)).tw,kw.
9. ((information or education*) adj3 (workshop* or handout or session* or printed or print or online or internet or booklet* or poster* or
written material* or paper-based or pamphlet* or brochure* or leaflet* or circular* or flyer* or program* or knowledge)).tw,kw.
10.((print or printed or education*) adj2 intervention*).tw,kw.







18.exp animal/ not human/
19.17 not 18
20.13 and 19
Lines #14-16, RCT filter. Hedge Best balance of sensitivity and specificity filter for identifying randomised trials in Embase.
hiru.mcmaster.ca/hiru/HIRU_Hedges_EMBASE_Strategies.aspx
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